Susquehanna International Group
KLRS

Susquehanna International Group’s Kalaris Therapeutics KLRS Stock Holding History

Susquehanna International Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-874
Closed -$43.2K – 13466
2023
Q3 		$43.2K Sell
874
-817
-48% -$55.7K ﹤0.01% 11363
2023
Q2 		$132K Buy
+1,691
New +$161K ﹤0.01% 10699
2022
Q1 		– Sell
-687
Closed -$204K – 14152
2021
Q4 		$204K Buy
+687
New +$319K ﹤0.01% 11405

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group's KLRS Position: Q1 2026 in Review

Susquehanna International Group increased its Kalaris Therapeutics (KLRS) stake by 310% in Q1 2026, buying an estimated $353K and bringing the position to 52,684 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #10819.

Susquehanna International Group first reported a position in KLRS in Q4 2020 and has held it in 19 quarters since. The position peaked at $1.67M in Q1 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Susquehanna International Group held 52,684 shares of Kalaris Therapeutics worth $304K as of Q1 2026.
  • Susquehanna International Group bought 39,828 Kalaris Therapeutics shares in Q1 2026, an estimated $353K.
  • Kalaris Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10819 holding.
  • Susquehanna International Group first reported a position in Kalaris Therapeutics in Q4 2020 and has held it in 19 quarters since.
  • Susquehanna International Group's Kalaris Therapeutics position peaked at $1.67M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.